Literature DB >> 11087636

Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?

P S Sinha1, S Bendall, T Bates.   

Abstract

AIM: The routine tumour grading of invasive ductal carcinoma of the breast has been shown to be a robust determinant of outcome but pathologists have been reluctant to grade lobular cancers. The aim of this study was to determine the prognostic significance of the routine reporting of lobular grade.
METHODS: All patients with invasive lobular carcinoma (ILC) treated between 1981 and 1996 were reviewed. Patients with ILC which had been graded were included in the study. These cases were matched with two control patients with invasive ductal carcinoma (IDC) who were operated on in the same year and were closest to the patients in age. Recurrence-free survival was compared with grade for ILC cases and IDC controls using life-table analysis. Similar comparisons were made with the Nottingham Prognostic Index (NPI) between the different prognostic groups.
RESULTS: Of 139 cases with ILC, 33 were excluded from the study because 24 were ungraded, five had advanced disease and four had mixed tumours. The mean length of follow-up for ILC cases was 75 months vs 70 months for IDC controls. Recurrence rates for grade I were 10% ILC vs 24% IDC, for grade II 32%vs 32% and for grade III 33%vs 49%. The reported grades for ILC and IDC both showed the expected trend for an increased recurrence rate with more severe tumour grade, but this was only significant for IDC grade II vs grade III (P<0.02) on life-table analysis; only 6% of lobular cancers were reported as grade III. However, there was significant separation of the survival curves when NPI was compared for both lobular and ductal cancers.
CONCLUSION: The routine reporting of tumour grade for ILC did not show significant difference in outcome between grade I and grade II, and very few tumours were rated grade III. The validity of grading lobular cancer of the breast requires further evaluation. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11087636     DOI: 10.1053/ejso.2000.0994

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas.

Authors:  Vanisri Raviraj; Hui Zhang; Hsin-ya Chien; Louise Cole; Erik W Thompson; Lilian Soon
Journal:  Clin Exp Metastasis       Date:  2012-01-22       Impact factor: 5.150

2.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Authors:  Ossama Tawfik; Bruce F Kimler; Marilyn Davis; Christopher Stasik; Sue-Min Lai; Matthew S Mayo; Fang Fan; John K Donahue; Ivan Damjanov; Patricia Thomas; Carol Connor; William R Jewell; Holly Smith; Carol J Fabian
Journal:  Virchows Arch       Date:  2007-04-26       Impact factor: 4.064

3.  Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes.

Authors:  R A Wascher; P J Bostick; K T Huynh; R Turner; K Qi; A E Giuliano; D S Hoon
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

4.  Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.

Authors:  Ulrik Narbe; Pär-Ola Bendahl; Dorthe Grabau; Lisa Rydén; Christian Ingvar; Mårten Fernö
Journal:  Springerplus       Date:  2014-02-06

5.  Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients.

Authors:  Anna M Badowska-Kozakiewicz; Anna Liszcz; Maria Sobol; Janusz Patera
Journal:  Arch Med Sci       Date:  2016-03-04       Impact factor: 3.318

Review 6.  Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.

Authors:  Xiufang Xu; Miaofeng Zhang; Faying Xu; Shaojie Jiang
Journal:  Mol Cancer       Date:  2020-11-24       Impact factor: 27.401

7.  Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.

Authors:  Monica J Engstrøm; Signe Opdahl; Lars J Vatten; Olav A Haugen; Anna M Bofin
Journal:  Histopathology       Date:  2014-12-22       Impact factor: 5.087

8.  EZH2 expression in invasive lobular carcinoma of the breast.

Authors:  SiGyun Roh; Shin Young Park; Hyoung Suk Ko; Jang Sihn Sohn; Eun Jung Cha
Journal:  World J Surg Oncol       Date:  2013-11-22       Impact factor: 2.754

9.  Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.

Authors:  Guangfu Hu; Guangxia Hu; Chengjiao Zhang; Xiaoyan Lin; Ming Shan; Yanmin Yu; Yongwei Lu; Ruijie Niu; Hui Ye; Cheng Wang; Cheng Xu
Journal:  BMC Cancer       Date:  2020-02-21       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.